A plant that could be the most effective cure for the flu could be in your pantry at any moment.
A little-known plant known as the Medicinal Herb of the Millenium, or MHOM, has the ability to cure more than 60% of people with flu, according to the makers of a drug used to treat the virus.
The MHOM was created by the United States Food and Drug Administration in 1998 as a supplement to standard drugs used to control influenza.
The FDA has approved the herb for use in treating influenza, but it has not been widely used in the U.S. for decades.
The plant is native to South America, and has been used in India and South America for centuries, said Dr. Michael Filippi, president of the Pharmaceutical Research Foundation, which has researched MHOM.
The new plant is derived from the seeds of the medicinal plant called Artemisia absinthium, which is found in Africa and China.
The plant’s leaves, bark and roots are used to make tea and other medicines, but the medicinal plants are also used in traditional Chinese medicine, and there is evidence that the plant is useful for treating flu.
The herb is believed to be as effective as standard flu shots, but unlike flu shots in many ways, the new herb is not administered intravenously.
In addition to being a relatively inexpensive drug, MHOM can be taken orally or taken in pills.
It is also believed to have fewer side effects than other flu vaccines, which have been linked to a variety of adverse reactions including fever, muscle aches and headaches.
In recent years, more than 2.7 million Americans have been hospitalized for flu-related complications, and the number of Americans who died from the disease has nearly doubled, according a 2015 report from the Centers for Disease Control and Prevention.
While the herb has been widely studied, it is not yet widely used by the public, and researchers have not made any conclusive claims about its effectiveness.
But the MHOM is one of the most potent treatments available for flu, and a new study published in the journal Antiviral Medicine suggests that it could be an effective vaccine candidate.
The findings could be a breakthrough for the FDA and other drug companies.
If the drug can be approved for use, it could reduce the number and severity of flu-associated complications, said study co-author Dr. Mark Rabinowitz, a professor of medicine at the University of California, San Francisco.
The study also found that the MHAM drug is safe and effective in patients with influenza and their families, but cautioning that further research is needed to fully understand its potential efficacy.
For now, the FDA has allowed the herb to be used for the first time in a clinical trial of flu vaccine candidates, which include the vaccine made by Gilead Sciences.
The company says it hopes to start administering the MHom in a vaccine trial in the next two to four months.
The trial is part of an effort to test the effectiveness of two different vaccines that the FDA approved in June.
The drug could become available in the first quarter of 2019.
The FDA’s decision to allow the herb is significant because it gives the agency more time to gather data and conduct studies on the drug before deciding to make any final decisions, Rabinowitsaid.
In the meantime, the agency should continue to closely monitor how the herb works and make sure it is safe for use before approving it for any clinical trials, Raffaello said.